Developer docs
API playgroundTry for free, no card

Search company profiles

Jetema

Full company profile

uuid000at1k

Namestring
Jetema
Legal namestring
JETEMA, Co., Ltd.
Websiteurl
jetema.com
Company typeenum
Public
Founded yearint
2009
Descriptiontext

JETEMA, Co., Ltd. is a Korean research-oriented bio-aesthetic pharmaceutical company founded in 2009 and headquartered in Wonju, South Korea. The company develops, manufactures, and commercializes a comprehensive portfolio of aesthetic medicine products spanning four categories: pharmaceutical products (JETEMA THE TOXIN, a botulinum toxin type A), medical devices (e.p.t.q. hyaluronic acid dermal fillers, epiticon PDO lifting threads, Ecolla PLLA skin booster), mesotherapy solutions (vitten), and cosmetics (Vitten, EXO'LUTION, e.p.t.q. Skin Care, e.p.t.q. By.derm). Its core technology rests on proprietary low-modification-degree HA filler manufacturing (achieving 1.89% MoD versus competitor benchmarks of 6-8%) and legitimate commercialization rights to the ATCC3502 botulinum toxin strain acquired in 2016, produced at Korea's largest cGMP-compliant botulinum toxin manufacturing facility.

JETEMA generates revenue through a hybrid B2B model: direct sales to aesthetic and plastic surgery clinics in its domestic Korean market, combined with exclusive supply and out-licensing contracts with regional pharmaceutical distributors across China, Brazil, the UK, Russia, the Middle East, Vietnam, Thailand, and other markets. The company has signed mega-distribution deals including a $459 million supply contract with Huadong Ningbo Medicine for China and a $120 million contract with Funshine for Brazil. JETEMA listed on KOSDAQ (ticker: 332570) in November 2019, reported 40% average annual sales growth over the four years through 2023, and has established wholly-owned subsidiaries in the United States (Irvine, CA, 2022) and China (Shanghai, 2021) to support FDA clinical trials and direct market entry. Recent regulatory milestones include Korean KFDA marketing authorization for THE TOXIN (December 2024), domestic Korean launch (March 2025), and NMPA approval for e.p.t.q. S500 in China (April 2025). The company is co-led by CEOs Kim Jaeyoung and Nam Jeongsun and operates manufacturing facilities in Wonju and Yongin alongside a global R&D center in Pangyo.

Short descriptiontext

Jetema is a Korean bio-aesthetic pharmaceutical company that develops, manufactures, and globally commercializes botulinum toxin, hyaluronic acid fillers, PDO lifting threads, and skin boosters for medical aesthetic clinics, primarily through exclusive international distribution contracts and direct Korean sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
aesthetic medicine products, botulinum toxin pharmaceuticals, hyaluronic acid fillers, PDO lifting threads, medical device manufacturing
Industry3 codes
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADANAC
Hand & Body Care (Lotions, Creams, Body Oils)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Consumer Fragrances & Personal Care Manufacturing (Non-cosmetic)
SECONDARYCRADAMAF
Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Soap and Cleaning Compound Manufacturing32561
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Perfumes, Cosmetics & Other Toilet Preparations2844
Product category
Aesthetic Medicine Pharmaceuticals and Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Pharmaceutical Products
TypeOne Time License
Description

Revenue from botulinum toxin products (JETEMA THE TOXIN) sold for both domestic Korean market and export. The company has obtained domestic marketing authorization for THE TOXIN 100U and is expanding clinical trials globally.

jetema.com
2Medical Devices
TypeOne Time License
Description

Revenue from HA fillers (e.p.t.q.), PDO threads (Epiticon), and medical device moisturizers (By.derm). Products sold through distributors globally.

jetema.com
3Cosmetics
TypeOne Time License
Description

Revenue from cosmetics products including Vitten, EXO'LUTION, e.p.t.q. Skin Care, and By.derm products sold through various channels.

jetema.com
4Meso Solutions
TypeOne Time License
Description

Revenue from meso solution products like Vitten for aesthetic medicine applications.

jetema.com
5Licensing and Supply Contracts
TypeLicensing Royalties
Description

Revenue from out-licensing agreements and exclusive supply contracts with international partners including $459M contract with Huadong Ningbo Medicine for China market.

en.sedaily.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1JETEMA THE TOXIN
Description

Botulinum toxin pharmaceutical product (For export)

jetema.com
+9 more records
Core offering1 text field

Jetema develops, manufactures, and sells pharmaceutical products (botulinum toxin JETEMA THE TOXIN), medical devices (e.p.t.q. HA dermal fillers, epiticon PDO lifting threads, Ecolla PLLA skin booster, prajué PN skin booster), meso solutions (vitten), and cosmetics (Vitten, EXO'LUTION, e.p.t.q. Skin Care, e.p.t.q. By.derm) for the global aesthetic medicine market, sold through exclusive regional distributors and wholly-owned subsidiaries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 40% average annual sales growth rate over four years
+1 more record
Product overview1 text field

JETEMA is a bio venture company that develops and manufactures pharmaceutical products, medical devices, and cosmetics for the aesthetic medicine market. The product portfolio is organized into four main categories: (1) Pharmaceutical Products — JETEMA THE TOXIN® (botulinum toxin type A for export); (2) Medical Devices — including the e.p.t.q.® HA dermal filler line (with lidocaine variants S100/S300/S500), epiticon® PDO lifting threads (Original and Thin), and Ecolla™ PLLA skin booster; (3) Meso Solutions — vitten® mesotherapy products including an injector device; (4) Cosmetics — including Vitten®, EXO'LUTION® skinbooster, e.p.t.q.® Skin Care, and e.p.t.q. By.derm® medical device moisturizers. Recent launches include prajué (PN skin booster, July 2024), Ecolla S (PLLA skin booster, August 2024), 순수필 HA filler (April 2024), and Lénafill HA filler (March 2023). The company operates cGMP-compliant manufacturing facilities in Wonju and Yongin, Korea.

Product and service9 records
1JETEMA THE TOXIN
CategoryPharmaceutical Product
Description

Botulinum toxin type A pharmaceutical product approved for improving glabellar lines, with Phase 2 clinical trials approved by U.S. FDA and ongoing Phase 3 trials in China and Korea for additional indications including upper limb muscle spasticity. Sold for both domestic Korean market and international export.

2e.p.t.q.
CategoryMedical Device
Description

Hyaluronic acid dermal filler product line with proprietary low-MoD (1.89%) technology, available in lidocaine variants S100, S300, and S500 in 0.5ml, 1.0ml, and 2.0ml volumes for facial dermal filling procedures. CE marked, ANVISA approved, and NMPA (China) approved.

3epiticon
CategoryMedical Device
Description

Polydioxanone (PDO) lifting thread product line (Original and Thin variants) for facial and body lifting procedures, backed by patents in Thailand and Russia. Manufactured at Jetema's PDO suture factory established in April 2023.

4Ecolla
CategoryMedical Device
Description

PLLA (poly-L-lactic acid) skin booster product line for skin rejuvenation applications, launched in August 2024.

5vitten
CategoryMeso Solution
Description

Meso solution product line for mesotherapy treatments, including an injector device, used by aesthetic medicine practitioners for skin rejuvenation procedures.

6EXO'LUTION
CategoryCosmetics
Description

Skinbooster product for skin hydration and rejuvenation, launched in Korea in January 2023.

7Lenafill
CategoryMedical Device
Description

Hyaluronic acid filler launched in Korea in March 2023 as a new HA filler offering in Jetema's filler portfolio.

8prajué
CategoryCosmetics
Description

PN (polynucleotide) skin booster launched in Korea in July 2024 for skin rejuvenation applications.

9e.p.t.q. By.derm MD
CategoryCosmetics
Description

Medical device moisturizer cream for protecting skin with damaged barriers, part of the e.p.t.q. By.derm medical device moisturizer line.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Huadong Ningbo Medicine
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-08-04
Description

$459 million supply contract with $12.5 million advance license fee for entering Chinese toxin market. Huadong Ningbo will initiate local clinical trial for marketing license in China and achieve local approval.

jetema.com
2epique UK Ltd
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-07-17
Description

$12 million supply contract for e.p.t.q. filler covering UK and Ireland markets.

jetema.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-04-20
Description

Joint development MOU for botulinum toxin product. Agreement aims for new indication development and approval through mutual cooperation and joint study.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-04-01
Description

$6.6 million exclusive supply contract for hyaluronic acid filler, recognizing excellent safety and efficacy of Jetema's filler e.p.t.q.

5NEDAL
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-03-24
Description

5-year partnership with Jordan company for exclusive supply of e.p.t.q. filler worth $2.5 million. License acquisition within 6 months required.

jetema.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-02-03
Description

$120 million supply contract and local clinical trial for THE TOXIN with Brazilian local company Funshine. Local marketing approval and launching planned by 2023.

7Vietnamese Clinics
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-07-21
Description

Strategic partnership with famous aesthetic clinics in Vietnam following formal import and distribution license approval in April 2018. VIP launching ceremony held with ambassador Kwon Sang-woo.

jetema.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-06-08
Description

MOU for cooperative research and academic excellence program to build organic cooperation research system, conduct collaborative research through mutual exchange and cooperation, and train talented individuals.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Jetema partnered with Hanmi Pharmaceutical to repurpose a joint treatment product for cosmetic use, expanding beyond single-product revenue structures.

Recent move13 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Evolus
TypeEmerging player
Description

US-focused aesthetic company marketing Jeuveau (prabotulinumtoxinA), a botulinum toxin positioned as a value alternative to Botox. Evolus represents the type of focused toxin challenger Jetema would face upon potential US entry.

TypeBroad incumbent
Description

Owner of Botox (botulinum toxin) and the broader aesthetic medicine franchise including CoolSculpting. AbbVie/Allergan is the global market leader in aesthetic toxins and the primary competitive incumbent Jetema's THE TOXIN would need to displace in the US and Europe.

TypeDirect peer
Description

Korean pharma company that developed Nabota, a botulinum toxin that received FDA approval. Daewoong competes with Jetema in both domestic Korean toxin markets and in the global export channels where Korean aesthetic products are positioned.

TypeBroad incumbent
Description

Aesthetic division of Merz Group offering Xeomin (botulinum toxin), Belotero (HA filler), Radiesse (CaHA), and Ultherapy. Merz competes with Jetema across both the toxin and filler categories globally.

TypeBroad incumbent
Description

Global dermatology-focused company producing the Juvederm and Restylane HA filler families, Sculptra (PLLA), and other aesthetic products. Galderma is the leading HA filler incumbent whose MoD and crosslinking technology Jetema explicitly benchmarks its e.p.t.q. fillers against.

TypeDirect peer
Description

Korean manufacturer of Botulax (botulinum toxin type A) and dermal fillers, with both domestic Korean market presence and expanding global distribution. Hugel is the most direct comparable to Jetema's THE TOXIN and e.p.t.q. filler portfolio and competes head-to-head in Korea and emerging markets.

TypeDirect peer
Description

Korean biopharmaceutical company developing Neuronox (botulinum toxin) and aesthetic products including fillers. Medytox overlaps directly with Jetema's core toxin and filler portfolio and shares the Korean-origin export narrative into US and emerging markets.

8Revance Therapeutics
TypeEmerging player
Description

Aesthetic and therapeutic company developing DaxibotulinumtoxinA (Daxxify), a long-duration botulinum toxin, plus the RHA Collection of fillers. Revance is a US-based emerging aesthetic competitor overlapping with Jetema's toxin and filler ambitions.

TypeEmerging player
Description

Austria-headquartered company specializing in HA fillers (Princess series), PDO threads, and aesthetic medicine products sold primarily in Europe and emerging markets. Croma is comparable to Jetema as a non-incumbent aesthetic specialist with parallel product categories including threads.

TypeBroad incumbent
Description

Global pharmaceutical company that markets Dysport/Azzalure botulinum toxin and other aesthetic products. Ipsen is one of the major global aesthetic toxin competitors alongside Botox and Xeomin.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Jetema

Aesthetic Medicine Pharmaceuticals and Medical Devicesjetema.com

Jetema is a Korean bio-aesthetic pharmaceutical company that develops, manufactures, and globally commercializes botulinum toxin, hyaluronic acid fillers, PDO lifting threads, and skin boosters for medical aesthetic clinics, primarily through exclusive international distribution contracts and direct Korean sales.

What Jetema does

JETEMA, Co., Ltd. is a Korean research-oriented bio-aesthetic pharmaceutical company founded in 2009 and headquartered in Wonju, South Korea. The company develops, manufactures, and commercializes a comprehensive portfolio of aesthetic medicine products spanning four categories: pharmaceutical products (JETEMA THE TOXIN, a botulinum toxin type A), medical devices (e.p.t.q. hyaluronic acid dermal fillers, epiticon PDO lifting threads, Ecolla PLLA skin booster), mesotherapy solutions (vitten), and cosmetics (Vitten, EXO'LUTION, e.p.t.q. Skin Care, e.p.t.q. By.derm). Its core technology rests on proprietary low-modification-degree HA filler manufacturing (achieving 1.89% MoD versus competitor benchmarks of 6-8%) and legitimate commercialization rights to the ATCC3502 botulinum toxin strain acquired in 2016, produced at Korea's largest cGMP-compliant botulinum toxin manufacturing facility.

JETEMA generates revenue through a hybrid B2B model: direct sales to aesthetic and plastic surgery clinics in its domestic Korean market, combined with exclusive supply and out-licensing contracts with regional pharmaceutical distributors across China, Brazil, the UK, Russia, the Middle East, Vietnam, Thailand, and other markets. The company has signed mega-distribution deals including a $459 million supply contract with Huadong Ningbo Medicine for China and a $120 million contract with Funshine for Brazil. JETEMA listed on KOSDAQ (ticker: 332570) in November 2019, reported 40% average annual sales growth over the four years through 2023, and has established wholly-owned subsidiaries in the United States (Irvine, CA, 2022) and China (Shanghai, 2021) to support FDA clinical trials and direct market entry. Recent regulatory milestones include Korean KFDA marketing authorization for THE TOXIN (December 2024), domestic Korean launch (March 2025), and NMPA approval for e.p.t.q. S500 in China (April 2025). The company is co-led by CEOs Kim Jaeyoung and Nam Jeongsun and operates manufacturing facilities in Wonju and Yongin alongside a global R&D center in Pangyo.

Jetema firmographics

Firmographics
Name
Jetema
Legal name
JETEMA, Co., Ltd.
Website
https://jetema.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Jetema is a Korean bio-aesthetic pharmaceutical company that develops, manufactures, and globally commercializes botulinum toxin, hyaluronic acid fillers, PDO lifting threads, and skin boosters for medical aesthetic clinics, primarily through exclusive international distribution contracts and direct Korean sales.
Ownership category
akta.pro rank

Jetema industry classification

Industry
Product category
Aesthetic Medicine Pharmaceuticals and Medical Devices
NAICS
Medicinal and Botanical Manufacturing (325411), Soap and Cleaning Compound Manufacturing (32561)
SIC
Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844)
akta.pro industry
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADANAC
Hand & Body Care (Lotions, Creams, Body Oils)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Consumer Fragrances & Personal Care Manufacturing (Non-cosmetic)
SECONDARYCRADAMAF
Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Aesthetic medicine products
  • Botulinum toxin pharmaceuticals
  • Hyaluronic acid fillers
  • PDO lifting threads
  • Medical device manufacturing

Where Jetema is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices6 records

Markets served

Jetema business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Products: Revenue from botulinum toxin products (JETEMA THE TOXIN) sold for both domestic Korean market and export. The company has obtained domestic marketing authorization for THE TOXIN 100U and is expanding clinical trials globally.
  2. Medical Devices: Revenue from HA fillers (e.p.t.q.), PDO threads (Epiticon), and medical device moisturizers (By.derm). Products sold through distributors globally.
  3. Cosmetics: Revenue from cosmetics products including Vitten, EXO'LUTION, e.p.t.q. Skin Care, and By.derm products sold through various channels.
  4. Meso Solutions: Revenue from meso solution products like Vitten for aesthetic medicine applications.
  5. Licensing and Supply Contracts: Revenue from out-licensing agreements and exclusive supply contracts with international partners including $459M contract with Huadong Ningbo Medicine for China market.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels7 records

Jetema product offering

Product offering

Core offering

Jetema develops, manufactures, and sells pharmaceutical products (botulinum toxin JETEMA THE TOXIN), medical devices (e.p.t.q. HA dermal fillers, epiticon PDO lifting threads, Ecolla PLLA skin booster, prajué PN skin booster), meso solutions (vitten), and cosmetics (Vitten, EXO'LUTION, e.p.t.q. Skin Care, e.p.t.q. By.derm) for the global aesthetic medicine market, sold through exclusive regional distributors and wholly-owned subsidiaries.

Product overview

JETEMA is a bio venture company that develops and manufactures pharmaceutical products, medical devices, and cosmetics for the aesthetic medicine market. The product portfolio is organized into four main categories: (1) Pharmaceutical Products — JETEMA THE TOXIN® (botulinum toxin type A for export); (2) Medical Devices — including the e.p.t.q.® HA dermal filler line (with lidocaine variants S100/S300/S500), epiticon® PDO lifting threads (Original and Thin), and Ecolla™ PLLA skin booster; (3) Meso Solutions — vitten® mesotherapy products including an injector device; (4) Cosmetics — including Vitten®, EXO'LUTION® skinbooster, e.p.t.q.® Skin Care, and e.p.t.q. By.derm® medical device moisturizers. Recent launches include prajué (PN skin booster, July 2024), Ecolla S (PLLA skin booster, August 2024), 순수필 HA filler (April 2024), and Lénafill HA filler (March 2023). The company operates cGMP-compliant manufacturing facilities in Wonju and Yongin, Korea.

Differentiator

Problem solved

Functional benefit

Brands

  • JETEMA THE TOXIN: Botulinum toxin pharmaceutical product (For export)
  • e.p.t.q.
  • epiticon
  • Vitten
  • EXO'LUTION
  • e.p.t.q. By.derm
  • e.p.t.q. Skin Care
  • Ecolla
  • Lenafill
  • prajué

Products and services

  • JETEMA THE TOXIN Botulinum toxin type A pharmaceutical product approved for improving glabellar lines, with Phase 2 clinical trials approved by U.S. FDA and ongoing Phase 3 trials in China and Korea for additional indications including upper limb muscle spasticity. Sold for both domestic Korean market and international export.
  • e.p.t.q. Hyaluronic acid dermal filler product line with proprietary low-MoD (1.89%) technology, available in lidocaine variants S100, S300, and S500 in 0.5ml, 1.0ml, and 2.0ml volumes for facial dermal filling procedures. CE marked, ANVISA approved, and NMPA (China) approved.
  • epiticon Polydioxanone (PDO) lifting thread product line (Original and Thin variants) for facial and body lifting procedures, backed by patents in Thailand and Russia. Manufactured at Jetema's PDO suture factory established in April 2023.
  • Ecolla PLLA (poly-L-lactic acid) skin booster product line for skin rejuvenation applications, launched in August 2024.
  • vitten Meso solution product line for mesotherapy treatments, including an injector device, used by aesthetic medicine practitioners for skin rejuvenation procedures.
  • EXO'LUTION Skinbooster product for skin hydration and rejuvenation, launched in Korea in January 2023.
  • Lenafill Hyaluronic acid filler launched in Korea in March 2023 as a new HA filler offering in Jetema's filler portfolio.
  • prajué PN (polynucleotide) skin booster launched in Korea in July 2024 for skin rejuvenation applications.
  • e.p.t.q. By.derm MD Medical device moisturizer cream for protecting skin with damaged barriers, part of the e.p.t.q. By.derm medical device moisturizer line.

Quantifiable outcome

  • 40% average annual sales growth rate over four years
  • +1 more outcomes

Companies that use Jetema

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Jetema technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Jetema partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, major and minor.

  • Huadong Ningbo MedicinecoreChannel Partner/ Reseller/ Distributor · 4 August 2020$459 million supply contract with $12.5 million advance license fee for entering Chinese toxin market. Huadong Ningbo will initiate local clinical trial for marketing license in China and achieve local approval.
  • epique UK LtdmajorChannel Partner/ Reseller/ Distributor · 17 July 2020$12 million supply contract for e.p.t.q. filler covering UK and Ireland markets.
  • Dong Wha PharmcoreStrategic or Co-development Partner · 20 April 2020Joint development MOU for botulinum toxin product. Agreement aims for new indication development and approval through mutual cooperation and joint study.
  • Russian CompanymajorChannel Partner/ Reseller/ Distributor · 1 April 2020$6.6 million exclusive supply contract for hyaluronic acid filler, recognizing excellent safety and efficacy of Jetema's filler e.p.t.q.
  • NEDALmajorChannel Partner/ Reseller/ Distributor · 24 March 20205-year partnership with Jordan company for exclusive supply of e.p.t.q. filler worth $2.5 million. License acquisition within 6 months required.
  • FunshinecoreChannel Partner/ Reseller/ Distributor · 3 February 2020$120 million supply contract and local clinical trial for THE TOXIN with Brazilian local company Funshine. Local marketing approval and launching planned by 2023.
  • Vietnamese ClinicsmajorChannel Partner/ Reseller/ Distributor · 21 July 2018Strategic partnership with famous aesthetic clinics in Vietnam following formal import and distribution license approval in April 2018. VIP launching ceremony held with ambassador Kwon Sang-woo.
  • Kyung Hee University, College of PharmacyminorStrategic or Co-development Partner · 8 June 2018MOU for cooperative research and academic excellence program to build organic cooperation research system, conduct collaborative research through mutual exchange and cooperation, and train talented individuals.
  • Hanmi PharmaceuticalcoreStrategic or Co-development PartnerJetema partnered with Hanmi Pharmaceutical to repurpose a joint treatment product for cosmetic use, expanding beyond single-product revenue structures.

Scale indicators11 records

Recent moves13 records

Expansion highlights6 records

Jetema competitors and assessment

Company assessment

Emerging players

  • Evolus: US-focused aesthetic company marketing Jeuveau (prabotulinumtoxinA), a botulinum toxin positioned as a value alternative to Botox. Evolus represents the type of focused toxin challenger Jetema would face upon potential US entry.
  • Revance Therapeutics: Aesthetic and therapeutic company developing DaxibotulinumtoxinA (Daxxify), a long-duration botulinum toxin, plus the RHA Collection of fillers. Revance is a US-based emerging aesthetic competitor overlapping with Jetema's toxin and filler ambitions.
  • Croma-Pharma: Austria-headquartered company specializing in HA fillers (Princess series), PDO threads, and aesthetic medicine products sold primarily in Europe and emerging markets. Croma is comparable to Jetema as a non-incumbent aesthetic specialist with parallel product categories including threads.

Broad incumbents

  • AbbVie (Allergan Aesthetics): Owner of Botox (botulinum toxin) and the broader aesthetic medicine franchise including CoolSculpting. AbbVie/Allergan is the global market leader in aesthetic toxins and the primary competitive incumbent Jetema's THE TOXIN would need to displace in the US and Europe.
  • Merz Aesthetics: Aesthetic division of Merz Group offering Xeomin (botulinum toxin), Belotero (HA filler), Radiesse (CaHA), and Ultherapy. Merz competes with Jetema across both the toxin and filler categories globally.
  • Galderma: Global dermatology-focused company producing the Juvederm and Restylane HA filler families, Sculptra (PLLA), and other aesthetic products. Galderma is the leading HA filler incumbent whose MoD and crosslinking technology Jetema explicitly benchmarks its e.p.t.q. fillers against.
  • Ipsen: Global pharmaceutical company that markets Dysport/Azzalure botulinum toxin and other aesthetic products. Ipsen is one of the major global aesthetic toxin competitors alongside Botox and Xeomin.

Direct peers

  • Daewoong Pharmaceutical: Korean pharma company that developed Nabota, a botulinum toxin that received FDA approval. Daewoong competes with Jetema in both domestic Korean toxin markets and in the global export channels where Korean aesthetic products are positioned.
  • Hugel: Korean manufacturer of Botulax (botulinum toxin type A) and dermal fillers, with both domestic Korean market presence and expanding global distribution. Hugel is the most direct comparable to Jetema's THE TOXIN and e.p.t.q. filler portfolio and competes head-to-head in Korea and emerging markets.
  • Medytox: Korean biopharmaceutical company developing Neuronox (botulinum toxin) and aesthetic products including fillers. Medytox overlaps directly with Jetema's core toxin and filler portfolio and shares the Korean-origin export narrative into US and emerging markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Jetema social profiles

Digital presence

Jetema compliance and trust

Trust signal

Compliance10 records

Jetema financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Jetema leadership team

Management profile

Number of profiles

Profiles3 records

Jetema subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Jetema funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Jetema M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jetema

What does Jetema do?

Jetema develops, manufactures, and sells pharmaceutical products (botulinum toxin JETEMA THE TOXIN), medical devices (e.p.t.q. HA dermal fillers, epiticon PDO lifting threads, Ecolla PLLA skin booster, prajué PN skin booster), meso solutions (vitten), and cosmetics (Vitten, EXO'LUTION, e.p.t.q. Skin Care, e.p.t.q. By.derm) for the global aesthetic medicine market, sold through exclusive regional distributors and wholly-owned subsidiaries.

Is Jetema a public or private company?

Jetema is a public company. It is classified as public and is currently operating.

When was Jetema founded?

Jetema was founded in 2009. It employs 11 to 50 people.

Where is Jetema based?

Jetema is headquartered in Seoul, South Korea, in the Asia region.

How does Jetema make money?

Five revenue lines are on record. Pharmaceutical Products are the primary driver. The others are medical Devices, cosmetics, meso Solutions and licensing and Supply Contracts.

Who are Jetema's main competitors?

Emerging players on record are Evolus, Revance Therapeutics and Croma-Pharma. Broad incumbents are AbbVie (Allergan Aesthetics), Merz Aesthetics, Galderma and Ipsen. Direct peers are Daewoong Pharmaceutical, Hugel and Medytox.

Does Jetema have an API?

No public API is recorded for Jetema.

What industry is Jetema in?

Jetema's product category is Aesthetic Medicine Pharmaceuticals and Medical Devices. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of CRADANAC, Hand & Body Care (Lotions, Creams, Body Oils). Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SedailyK-Aesthetics Firms Expand Portfolios Through Investment and M&AKorean aesthetic medicine companies Pharma Research, Hugel, and Jetema are accelerating portfolio expansion through investment and M&A to move beyond single-product revenue structures centered on toxins and fillers. Pharma Research disclosed plans to pursue M&A in medical devices and cosmetics to reduce dependence on its Rejuran skin booster, while Hugel signed a distribution agreement with Hans Biomed for an ECM-based skin booster and Jetema partnered with Hanmi Pharmaceutical to repurpose a joint treatment product for cosmetic use. The strategic moves come as intensifying competition from new entrants including ECM skin booster manufacturers and cosmetics companies entering the medical device market is pressuring established players to expand their product lines.Press9Jetema, aiming to expand its territory, bets on regenerative technology, 3D medical applications, and microneedles.Jetema is actively expanding its medical and bio venture portfolio through strategic investments in Gropec Bio, Morpheus, and Peroca to leverage advanced technologies such as recombinant proteins, 3D surgical simulations, and microneedles. The company is simultaneously preparing for entry into the U.S. botulinum toxin market, currently conducting Phase 2 clinical trials via its subsidiary Jetema USA. These moves are part of a broader strategy to diversify beyond existing filler and beauty markets by integrating these technologies into new painless treatment products.Thebell'Microneedle Patch' Feroca completes 10 billion Series B funding.Peroca completed a 10 billion won Series B funding round, with parent company Jetema investing 5 billion won alongside participants such as Welcome Capital and HB Investment. The funds will support Peroca's R&D efforts to commercialize its two-layer micro needle technology for applications including vaccines, gene therapies, and beauty products in collaboration with Jetema. Peroca has set an IPO target for 2025 with Kiwoom Securities as its underwriter.